XML 45 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Note 4 - Personnel Expenses, Including Share-based Remuneration (Tables)
12 Months Ended
Dec. 31, 2023
Statement Line Items [Line Items]  
Disclosure of personnel expenses including share-based remuneration [text block]
  

Year ended December 31,

 
  

2021

  

2022

  

2023

 

Salaries, including bonuses

 $43,440  $43,235  $41,890 

Social security contribution, excluding amounts related to share-based remuneration

  5,371   5,222   5,825 

External temporary hires

  8,617   10,318   11,796 

Defined contribution pension expense

  4,477   4,752   3,814 

Other personnel-related expenses

  2,080   1,758   2,476 

Total personnel expenses, excluding share-based remuneration

  63,984   65,285   65,801 

Share-based remuneration, including related social security contribution

  10,466   9,304   16,950 

Total personnel expenses, including share-based remuneration

 $74,450  $74,588  $82,750 
Disclosure of research and development expense [text block]
  

Year ended December 31,

 
  

2021

  

2022

  

2023

 

Total research and development expenditure

  44,055   50,537   46,098 

Less: Capitalized development expenditure excluded from personnel expenses (Note 10)

  4,862   6,825   4,587 

Net research and development expenditure recognized as part of personnel expenses

  39,193   43,713   41,511 
Disclosure of number and weighted average exercise prices of share options and other equity instruments [text block]
  

Opera: RSUs

  

Opera: Options

  

Kunlun: RSUs (1)

 
  

Number of RSUs

  

Weighted

average grant

date fair value

  

Number of

options

  

Weighted

average grant

date fair value

  

Number of RSUs

  

Weighted

average grant

date fair value

 

Outstanding as of January 1, 2022

  2,666,525  $9.71   100,000  $3.40   -  $- 

Granted during the year

  -   -   -   -   3,275,000   1.22 

Forfeited during the year

  (82,500)  9.97   -   -   (350,000)  1.22 

Exercised during the year

  (798,750)  9.25   -   -   -   - 

Expired during the year

  -   -   -   -   -   - 

Outstanding as of December 31, 2022

  1,785,275   9.90   100,000   3.40   2,925,000   1.22 

Regular grants during the year

  934,359   8.39   -   -   6,200,000   2.01 

Dividend adjustment grants during the year

  257,551   -   -   -   -   - 

Forfeited during the year

  (50,203)  8.66   -   -   (2,000,000)  1.68 

Exercised during the year

  (1,008,509)  8.37   (60,000)  1.92   (832,500)  1.10 

Expired during the year

  -   -   -   -   -   - 

Outstanding as of December 31, 2023

  1,918,473  $8.67   40,000  $5.62   6,292,500  $1.86 
Disclosure of indirect measurement of fair value of goods or services received, other equity instrument granted during period [text block]
  

Opera 2023

RSU grants (2)

  

Kunlun 2022

RSU grants

  

Kunlun 2023

RSU grants

 

Equity unit price valuation

 $8.46  $2.88  $3.48 

Model Used

 

Monte Carlo

  

Black-Scholes

  

Black-Scholes

 

Expected Volatility (%) (1)

  50.5%  25.5%  24.6%

Risk free interest rate (%) (1)

  4.9%  2.2%  2.1%

Duration of initial simulation period (years to longstop date)

  2.49   N/A   N/A 

Duration of second simulation period with postponed exercise (years)

  3.00   N/A   N/A 

Exercise price

 $-  $1.77  $1.54 

Fair value at the measurement date

 $8.39  $1.22  $2.01 
Disclosure of information about key management personnel [text block]
  

Year ended December 31,

 
  

2021

  

2022

  

2023

 

Short-term employee benefits

 $2,046  $2,371  $2,495 

Post-employment and medical benefits

  60   56   72 

Share-based payment transactions

  1,209   1,488   1,693 

Total compensation for key management personnel

 $3,315  $3,914  $4,260